A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A

Trial Profile

A low-interventional Multicentre Post-Authorisation Safety Study for Voncento/Biostate/Aleviate for Routine Prophylaxis, Treatment of Bleeding Events and/or Surgery in Male Subjects with Haemophilia A

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Factor VIII/von Willebrand factor (Primary)
  • Indications Haemophilia A; Perioperative haemorrhage
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 21 Mar 2018 Status changed to recruiting.
    • 13 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top